Terms: = Germ cell tumor AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C AND Prognosis
16 results:
1. LAIR1 drives glioma progression by nuclear focal adhesion kinase dependent expressions of cyclin D1 and immunosuppressive chemokines/cytokines.
Wei X; Pan S; Wang Z; Chen J; Lu L; Cao Q; Song S; Zhang H; Liu X; Qu X; Lin X; Xu H
Cell Death Dis; 2023 Oct; 14(10):684. PubMed ID: 37845206
[TBL] [Abstract] [Full Text] [Related]
2. Dysregulated ceramides metabolism via ptpn11 exposes a metabolic vulnerability to breast cancer metastasis.
Qiao S; Wang T; Wang H
Med Oncol; 2023 Sep; 40(11):310. PubMed ID: 37773553
[TBL] [Abstract] [Full Text] [Related]
3. ptpn11 variant may be a prognostic indicator of IDH-wildtype glioblastoma in a comprehensive genomic profiling cohort.
Otani R; Ikegami M; Yamada R; Yajima H; Kawamura S; Shimizu S; Tanaka S; Takayanagi S; Takami H; Yamaguchi T
J Neurooncol; 2023 Aug; 164(1):221-229. PubMed ID: 37552362
[TBL] [Abstract] [Full Text] [Related]
4. H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis.
Bin-Alamer O; Jimenez AE; Azad TD; Bettegowda C; Mukherjee D
World Neurosurg; 2022 Sep; 165():e251-e264. PubMed ID: 35697228
[TBL] [Abstract] [Full Text] [Related]
5. CLEC12B Decreases Melanoma Proliferation by Repressing Signal Transducer and Activator of Transcription 3.
Montaudié H; Sormani L; Dadone-Montaudié B; Heim M; Cardot-Leccia N; Tulic MK; Beranger G; Gay AS; Debayle D; Cheli Y; Raymond JH; Sohier P; Petit V; Rocchi S; Gesbert F; Larue L; Passeron T
J Invest Dermatol; 2022 Feb; 142(2):425-434. PubMed ID: 34310951
[TBL] [Abstract] [Full Text] [Related]
6. Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling.
Hou Y; Sun B; Liu W; Yu B; Shi Q; Luo F; Bai Y; Feng H
Theranostics; 2021; 11(2):555-566. PubMed ID: 33391492
[TBL] [Abstract] [Full Text] [Related]
7. Small-Molecule Inhibitors of shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
Mitra R; Ayyannan SR
ChemMedChem; 2021 Mar; 16(5):777-787. PubMed ID: 33210828
[TBL] [Abstract] [Full Text] [Related]
8. Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: A Review and Future Directions.
Alhumaid MS; Dasouki MJ; Ahmed SO; AbalKhail H; Hagos S; Wakil S; Hashmi SK
Acta Haematol; 2020; 143(6):583-593. PubMed ID: 32541138
[TBL] [Abstract] [Full Text] [Related]
9. Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion.
García-Romero N; Palacín-Aliana I; Esteban-Rubio S; Madurga R; Rius-Rocabert S; Carrión-Navarro J; Presa J; Cuadrado-Castano S; Sánchez-Gómez P; García-Sastre A; Nistal-Villan E; Ayuso-Sacido A
Cells; 2020 Jun; 9(6):. PubMed ID: 32516884
[TBL] [Abstract] [Full Text] [Related]
10. Integrated molecular profiling of juvenile myelomonocytic leukemia.
Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
[TBL] [Abstract] [Full Text] [Related]
11. cfc1 is a cancer stemness-regulating factor in neuroblastoma.
Chikaraishi K; Takenobu H; Sugino RP; Mukae K; Akter J; Haruta M; Kurosumi M; Endo TA; Koseki H; Shimojo N; Ohira M; Kamijo T
Oncotarget; 2017 Jul; 8(28):45046-45059. PubMed ID: 28620148
[TBL] [Abstract] [Full Text] [Related]
12. shp2 phosphatase as a novel therapeutic target for melanoma treatment.
Zhang RY; Yu ZH; Zeng L; Zhang S; Bai Y; Miao J; Chen L; Xie J; Zhang ZY
Oncotarget; 2016 Nov; 7(45):73817-73829. PubMed ID: 27650545
[TBL] [Abstract] [Full Text] [Related]
13. GBM-associated mutations and altered protein expression are more common in young patients.
Ferguson SD; Xiu J; Weathers SP; Zhou S; Kesari S; Weiss SE; Verhaak RG; Hohl RJ; Barger GR; Reddy SK; Heimberger AB
Oncotarget; 2016 Oct; 7(43):69466-69478. PubMed ID: 27579614
[TBL] [Abstract] [Full Text] [Related]
14. [Oncolytic potential of recombinant influenza A virus vectors on a model of malignant glioma in vivo].
Shurygina APS; Kartashev AV; Kovanko EG; Kiseleva LN; Pustovalov YI; Slita AK; Zarubaev VV; Belyaevskaya SV; Sirotkin AK; Kiselev OI; Egorov AY
Vopr Onkol; 2016; 62(1):138-45. PubMed ID: 30444592
[TBL] [Abstract] [Full Text] [Related]
15. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract] [Full Text] [Related]
16. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing.
Herrero Y Calle M; Cornelis JJ; Herold-Mende C; Rommelaere J; Schlehofer JR; Geletneky K
Int J Cancer; 2004 Mar; 109(1):76-84. PubMed ID: 14735471
[TBL] [Abstract] [Full Text] [Related]
